1/9/2017 12:00:00AM Received 1/9/2017 10:54:15AM 4/9/2017 ... · MLL gene have been reported. t(9;11)(p21-22;q23) resulting in MLL - AF9 fusion gene is the most common MLL abnormality

LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)

SECTOR - 18, BLOCK -E ROHINI DELHI 110085

Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 12:33:00PM

28/7/2020 2:36:47PM

25 Years Male153672155

UNKNOWN

DUMMY N037

29/7/2020 3:33:39PM

(Real Time PCR)

RESULTS

BCR-ABL gene rearrangement

Negative

Note

1. Sensitivity of the assay is 0.01% when copies of ABL detected is 100,000

2. Limit of detection is 10 copies of BCR-ABL fusion gene transcripts per PCR

3. This is an in-house developed assay designed as per EAC (Europe Against Cancer) protocol

4. This test detects Major (M) gene rearrangements namely- e13a2 & e14a2 and Minor (m) gene

arrangement e1a2. This test does not detect micro gene rearrangement e19a2

5. Test conducted on Whole blood / Bone Marrow

Comments

Chronic Myeloid Leukemia (CML) is the commonest myeloproliferative neoplasm and possibly the

commonest adult leukemia in India. This clonal stem cell disorder is characterized by a proliferation of

myeloid cells at all stages of differentiation and the t(9:22) (q34:q11) leading to formation of BCR-ABL

fusion gene. Cytogenetic and molecular studies are vital for the diagnosis of CML by using detection

procedures for Philadelphia chromosome. The abnormality is present in over 95% patients of CML while

remainder 5% have complex or variant translocations involving additional chromosomes. Major gene

rearrangements are detected in CML while minor gene rearrangement may be detected in ALL.

Uses

· To detect & monitor therapy in CML patients.

· As a prognostic marker in ALL patients. Presence of BCR-ABL gene rearrangement is associated with

poor prognosis.

Dr Anand Chandrasekaran Annan

MD (American Board of Pathology)

PhD (Molecular & Cellular Pathology)

HOD - Oncopathology

Dr Atul Thatai

PhD, Biotechnology

HOD Molecular Diagnostics

NRL - Dr Lal PathLabs Ltd

-------------------------------End of report --------------------------------

PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)

*153672155*

.

Page 1 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 12:33:00PM

28/7/2020 2:36:47PM


UNKNOWN

DUMMY N037

29/7/2020 3:33:39PM

IMPORTANT INSTRUCTIONS

*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .

*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample

repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen

circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit

request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive

jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact

customer care Tel No. +91-11-39885050 for all queries related to test results.

(#) Sample drawn from outside source.


*153672155*

.

Page 2 of 2


SECTOR - 18, BLOCK -E ROHINIDELHI 110085

Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 12:00:00AM

28/7/2020 2:36:04PM


UNKNOWN

DUMMY N038

29/7/2020 3:17:41PM

RESULTS

PML - RARA Type bcr 1

Negative

Note


2. Limit of detection is 10 copies of PML-RARA fusion gene transcripts per PCR


4. This test detects 3 types of translocations - bcr 1, bcr 2 & bcr 3


Comments

Acute Promyelocytic Leukemia (APL) is characterized by a unique reciprocal chromosomal translocation

t(15;17) (q22;q11-12) and its underlying fusion gene PML / RARA rearrangement. The fusion is seen between

Promyleocytic (PML) gene on chromosome 15 and RARA gene on chromosome 17. Based on PML

breakpoint location, the PML RARA transcripts subtype bcr 1 & bcr 2 (Long transcript type) and bcr 3 (Short

transcript type) may be formed.

Uses

· For diagnostic identification of PML RARA in cases of Acute Promyelocytic Leukemia

· To assess molecular resistance & predict response to treatments containing ATRA and / or ATO




HOD - Oncopathology

Dr Atul Thatai

PhD, Biotechnology



-------------------------------End of report --------------------------------


*153672165*

.

Page 1 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 12:00:00AM

28/7/2020 2:36:04PM


UNKNOWN

DUMMY N038

29/7/2020 3:17:41PM











*153672165*

.

Page 2 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 11:48:00AM

28/7/2020 2:34:20PM


UNKNOWN

DUMMY N045

29/7/2020 3:17:31PM

AML ETO GENE REARRANGEMENT t(8;21)(q22;q22);(RUNX1;RUNX1T1), PCR,

QUALITATIVE

TEST CONDUCTED

(Real Time PCR)

RESULTS

AML ETO t(8;21) Gene Rearrangement

Negative

Note


2. Limit of detection is 10 copies of 8;21 fusion gene transcripts per PCR



Comments

Cytogenetic aberrations play a central role in the classification of AML. These aberrations are detected in

50-70% cases of AML by using standard techniques. The AML1(CBFA2, RUNX1)-ETO (MTG8) gene fusion

results from the t(8;21)(q22;q22), which is the commonest chromosomal rearrangement associated with AML,

being detected in approximately 8% of AML cases in children and young adults. Most t(8;21) positive AML’s are

de novo leukemias - vast majority being M2 FAB subtype. This translocation creates chimeric genes encoding

fusion proteins that interfere with the function of CBFα and block the maturation of myeloid cells.

Uses

· For diagnostic identification of AML having morphological, imuunophenotypic or clinical features strongly

suggestive of translocation 8;21

· For prognostic evaluation - Presence of this translocation is associated with a favorable prognosis




HOD - Oncopathology

Dr Atul Thatai

PhD, Biotechnology



-------------------------------End of report --------------------------------


*153672179*

.

Page 1 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 11:48:00AM

28/7/2020 2:34:20PM


UNKNOWN

DUMMY N045

29/7/2020 3:17:31PM











*153672179*

.

Page 2 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 12:00:00AM

28/7/2020 2:35:56PM


UNKNOWN

DUMMY N051

29/7/2020 3:18:26PM

NPM1 GENE MUTATIONTEST CONDUCTED

(PCR, Fragment analysis)

RESULTS

NPM1 Gene Mutation

Negative

Note

1. This test detects all types of insertion/deletion NPM1 mutations

2. This is an in-house developed assay


Comments

Evaluation of NPM1 is recommended in cases of cytogenetically normal AML as detection of these mutations

in the absence of a FLT3 mutation or presence of FLT3 mutation with low allelic ratio (<50%) confers a

favourable prognosis confers a good prognosis and thus NPM1 mutations should always be interpreted with

results of FLT3 mutations. NPM1 mutations are class II mutations which impair hematopoietic differentiation

and subsequent apoptosis. They do not occur in combination with the recurrent cytogenetic abnormalities in

AML and may represent a biologically distinct entity. More than 10 types of NPM mutations have been reported;

types A, B, D together constitute >95% of the mutations.

Uses

· For prognostic evaluation of AML




HOD - Oncopathology

Dr Atul Thatai

PhD, Biotechnology



-------------------------------End of report --------------------------------


*153672167*

.

Page 1 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 12:00:00AM

28/7/2020 2:35:56PM


UNKNOWN

DUMMY N051

29/7/2020 3:18:26PM











*153672167*

.

Page 2 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 12:20:00PM

28/7/2020 2:35:46PM


UNKNOWN

DUMMY N052

29/7/2020 2:45:46PM

(PCR, Fragment analysis)

RESULTS

FLT3-ITD

Negative

Note

1. This test detects FLT3-internal tandem duplication (ITD) by fragment analysis on a capillary

electrophoresis system

2. This is an in-house developed assay


Comments

FLT3 mutations are class I mutations that occur in 30% AML with normal karyotype, AML with t (15; 17),

AML with t(6;9) and in AML with mutated NPM1. The mutations are most commonly internal tandem

duplications. There are also cases of point mutations within the tyrosine kinase domain. The presence of

FLT3 mutations confers a poorer prognosis than in similar cases without FLT3 mutations. Recent studies

indicate that AML with NPM1 mutation and FLT3-ITD low allelic ratio (<50%) may also have a more

favourable prognosis and such patients should not be routinely assigned to allogenic HCT. Also note that

this test is not designed for monitoring residual disease following treatment due to lower sensitivity than

required for MRD assessment.

Uses

· For prognostic evaluation of AML




HOD - Oncopathology

Dr Atul Thatai

PhD, Biotechnology



-------------------------------End of report --------------------------------


*153672170*

.

Page 1 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 12:20:00PM

28/7/2020 2:35:46PM


UNKNOWN

DUMMY N052

29/7/2020 2:45:46PM











*153672170*

.

Page 2 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 11:45:00AM

28/7/2020 2:34:09PM


UNKNOWN

DUMMY N062

29/7/2020 2:45:52PM

t(1;19) (q23;p13.3); TCF3- BX1(E2A-PBX1), PCR QUALITATIVETEST CONDUCTED

(Real Time PCR)

RESULTS

t (1;19) (q23 ;p13.3); TCF3-PBX1(E2A- PBX1)

Negative

Comments

Precursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children

and 20% in adults. Most patients with ALL show an abnormal clone by conventional cytogenetic

studies.The common chromosome translocations in pediatric ALL include t(1;19)(q23;p13.3);

TCF3-PBX1(E2A-PBX1), t(12;21) (p13;q22); ETV6-RUNX1(TEL-AML1) & MLL gene rearrangement. All

these translocations are important to detect as they are important prognostic markers. Detection of

translocation t(1;19) shows improved outcome with intensive chemotherapy.

Uses

· Quantifying disease before treatment and after therapy for patients with ALL

· Assessing residual disease after treatment




HOD - Oncopathology

Dr Atul Thatai

PhD, Biotechnology



-------------------------------End of report --------------------------------











*153672183*

.

Page 1 of 1



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 11:46:00AM

28/7/2020 2:34:11PM


UNKNOWN

DUMMY N063

29/7/2020 2:50:26PM

t(12;21) (p13;q22); ETV6-RUNX1 (TEL-AML1), PCR QUALITATIVETEST CONDUCTED

(Real Time PCR)

RESULTS

t (12; 21) (p13;q22); ETV6-RUNX1(TEL-AML1)

Negative

Comments

Precursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children and 20%

in adults. Most patients with ALL show an abnormal clone by conventional cytogenetic studies. The common

chromosome translocations in pediatric ALL include t(1;19) (q23 ;p13.3); TCF3-PBX1(E2A-PBX1), t(12; 21)

(p13;q22); ETV6-RUNX1(TEL-AML1) & MLL gene rearrangement. All these translocations are important to

detect as they are important prognostic markers. Detection of translocation t(12;21) which is commonest in

B-ALL is associated with good prognosis in children.

Uses






HOD - Oncopathology

Dr Atul Thatai

PhD, Biotechnology



-------------------------------End of report --------------------------------











*153672182*

.

Page 1 of 1



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 11:47:00AM

28/7/2020 2:34:14PM


UNKNOWN

DUMMY N064

29/7/2020 3:17:23PM

t(4;11) (q21;q23); (MLL-AF4), PCR QUALITATIVETEST CONDUCTED

(Real Time PCR)

RESULTS

t (4;11) (q21;q23); (MLL-AF4)

Negative

Comments

Precursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children and

20% in adults. Most patients with ALL show an abnormal clone by conventional cytogenetic studies. The

common chromosome translocations in pediatric ALL include t(1;19)(q23;p13.3);TCF3-PBX1(E2A- PBX1),

t(12;21)(p13;q22); ETV6-RUNX1(TEL-AML1) & MLL gene rearrangement. All these translocations are

important to detect as they are important prognostic markers. The t(4;11)(q21;q23) results in the MLL-AF4

fusion gene and is the most frequent MLL translocation in ALL but is rare in AML. Detection of translocation

t(4;11) is seen in 4-6% cases in children and adults. It is generally associated with a poor prognosis.

Uses






HOD - Oncopathology

Dr Atul Thatai

PhD, Biotechnology



-------------------------------End of report --------------------------------


*153672181*

.

Page 1 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 11:47:00AM

28/7/2020 2:34:14PM


UNKNOWN

DUMMY N064

29/7/2020 3:17:23PM











*153672181*

.

Page 2 of 2



Name

A/c Status

Lab No.

Ref By:

Gender: Age:

Report Status

Reported

Received

Collected

P Final

28/7/2020 12:00:00AM

28/7/2020 2:36:39PM


UNKNOWN

DUMMY N065

29/7/2020 3:19:20PM

t (11;19) (q23;p13.3); (MLL-ENL)TEST CONDUCTED

(Real Time PCR)

RESULTS

t (11;19) (q23;p13.3); (MLL-ENL)

Negative

Comments

Precursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children and

20% in adults. Most patients with ALL show an abnormal clone by conventional cytogenetic studies. The

common chromosome translocations in pediatric ALL include t(1;19) (q23;p13.3);TCF3-PBX1(E2A-PBX1),

t(12;21) (p13;q22); ETV6-RUNX1 (TEL-AML1) & MLL gene rearrangement. All these translocations are

important to detect as they are important prognostic markers. Translocation t(11;19) (q23;p13.3) generates

MLL-ENL fusion gene which is observed with equal frequency in AML & ALL.

Uses






HOD - Oncopathology

Dr Atul Thatai

PhD, Biotechnology



-------------------------------End of report --------------------------------











*153672162*

.

Page 1 of 1

LPL – LPL-ROHINI (NATIONAL REFERENCE LAB) SECTOR - 18, BLOCK -E ROHINI DELHI 110085

*153672142* Note : 1. Metaphases captured by Robotic Microscope 2. Karyogram attached

Name : DUMMY Q005

Lab No. : 153672142 Age : 34 Years Gender: Male

A/c Status : P Ref by : UNKNOWN

Collected: 28-07-2020 12:49:00 Received: 28-07-2020 14:39:04 Reported: 08/08/2020 19:20:05

Report Status: Revised

CHROMOSOME ANALYSIS FOR HEMATOLOGIC MALIGNANCY

Result Summary Normal/Abnormal

Interpretation

Normal Male karyotype. No numerical or structural chromosomal anomalies detected at 450-550 banding resolution. Advised: 1. Microdeletions and cryptic chromosome deletions may not be detected by this method. 2. Results to be clinically correlated.

Specimen Not Specified

Method 24 hr unstimulated cultures with appropriate serum & antibiotics

Banding Method Banding Resolution: 450-550

Stain Name

Cells Analysed

Cells Counted

Karyograms Prepared

GTG

TOTAL

Abbreviations: GTG=G-banding; QFQ=Q-banding;

DAPI=DAPI-staining; CBG=C-banding; AGNOR=Silver-staining; NON=Non-banded The sum of cells analyzed and cells counted equals the total cells examined.

Result* 46,XY

Reason for referral

To rule out any hematological malignancy

*Karyogram attached

.

Page 1 of 2

LPL – LPL-ROHINI (NATIONAL REFERENCE LAB) SECTOR - 18, BLOCK -E ROHINI DELHI 110085

*153672142* Note : 1. Metaphases captured by Robotic Microscope 2. Karyogram attached

Name : DUMMY Q005

Lab No. : 153672142 Age : 34 Years Gender: Male

A/c Status : P Ref by : UNKNOWN

Collected: 28-07-2020 12:49:00 Received: 28-07-2020 14:39:04 Reported: 08/08/2020 19:20:05

Report Status: Revised

Dr Saurabh Kumar Bhattacharya Dr Anand Chandrasekaran Annan

PhD, Cytogenetics MD (American Board of Pathology)

HOD Clinical Cytogenomics NRL - Dr Lal PathLabs Ltd

PhD (Molecular & Cellular Pathology) HOD - Oncopathology

This is a revised report & supersedes all the previously issued reports This is a revised report & supersedes all the previously issued reports

s


*Test results released pertain to the specimen submitted.*All test results are dependent on the quality of the sample received by the Laboratory.

*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring

Physician.*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to

unforeseen circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value.

Kindly submit request within 72 hours post reporting.*Test results may show interlaboratory variations.*The Courts/Forum at Delhi shall have

exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes.

*Contact customer care Tel No. +91-11-39885050 for all queries related to test results.


.

Page 2 of 2

Documents

1/9/2017 12:00:00AM Received 1/9/2017 10:54:15AM 4/9/2017 ... · MLL gene have been reported. t(9;11)(p21-22;q23) resulting in MLL - AF9 fusion gene is the most common MLL abnormality